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Abstract
1This paper examines the role of sex in the drug approval process. Medical literature
has explored in great depth the many ways in which men and women diﬀer, sometimes dra-
matically, often in ways that are seemingly unrelated to the physical, anatomical distinctions
between the two sexes. After years of intentionally excluding women from critical phases
of clinical drug trials, the FDA formally reversed such policies in the 1990s. A number of
prescription drugs recently removed from the market disproportionately harmed women as
compared to men. Loopholes in the current system have perpetuated the drug approval pro-
cess’s inadequate consideration for the needs of women, thereby subjecting them to a higher
level of risk. Eﬀorts to correct for the lack of drug trials aimed to ensure the safety and
eﬃcacy for pediatric patients are also reviewed to provide a contrast. While the intentional
biases in the system have been addressed, the current drug approval process fails to pro-
vide women with the same degree of protection as it does men. A number of issues remain
requiring additional study and consideration before a complete solution can be proposed.
2“Knowing is not enough; we must apply.
Willing is not enough; we must do.”
– Goethe1
Introduction
Men and women are diﬀerent. Sex matters. These two statements are inanely obvious. The harder issues
arise in discerning how, precisely, men and women are diﬀerent and when, exactly, sex matters.2 This is true
in a variety of circumstances, but perhaps not more relevant than with respect to health and medical care.
Medical and scientiﬁc advances operate necessarily on the level of generality. Research has indicated how
smoking aﬀects the body, but such knowledge cannot precisely predict how a particular smoker will fare.
Likewise, without individualized and in-depth study, it is impossible to predict the impact of a dietary regime
on any speciﬁc individual, but science can safely say that living on fast food will not optimize one’s health.
Many daily decisions regarding what we put in our bodies, including everything from the common and ha-
bitual consumption of breakfast cereals to the much more deliberate and radical decision to subject the body
to toxic cancer treatments, are made without absolute guarantees. Such guarantees would be impractical
and largely unnecessary. It is impossible to test, ex ante, how every known substance will impact each indi-
vidual. In addition, such testing would be an enormous waste of resources – discounting the possibility of
rare allergic reactions and the role of personal tastes, a bowl of Cheerios will aﬀect my body in pretty much
1Committee on Understanding the Biology of Sex and Gender Differences, Institute of Medicine, Exploring
the Biological Contributions to Human Health: Does Sex Matter?, title page ( Theresa M. Wizemann & Mary-Lou
Pardue eds., National Academy Press, 2001).
2Id. at ix.
3the same way as it will aﬀect yours. The same can be said for the majority of medical and drug treatments,
rendering individualized research unnecessary.
Instead of demanding individualized attention, we comfortably rely on statistics generated through research
to inﬂuence our personal decisions. Based on such general knowledge, I know that it is healthier for me to
eat the bowl of Cheerios based on, inter alia, calorie and ﬁber content, than to grab my preferred pop-tarts.
I do not need tailored information to show that Cheerios will be beneﬁcial to my body speciﬁcally; instead,
I am comfortable making this decision based on generally applicable considerations.
While ascribing such thinking to my choice of breakfast foods may seem ridiculous, the same concept may
seem more appropriate with regard to medical decisions. I have never been in a medical study, so I have
no way of knowing precisely how various chemical compounds aﬀect my physiology. Instead, like the over-
whelmingly majority of consumers, I rely on the packaging or the enclosed insert to give me the expected
range of reactions and eﬀects. For the overwhelmingly majority of cases and individuals, that information
will be more than suﬃcient, unless, as states above, some unique condition, such as allergy, is present. The
information drug manufacturers include in the packaging is derived from the studies and research mandated
by the Food and Drug Administration prior to marketing.
In order for my reliance on such information to be reasonable, it must be relevant to me, or at least as
relevant as possible for people physically like me. For this to be the case the subjects included in the sample
must be randomized, so that as many diﬀerent “kinds” of people are represented to obtain results gener-
ally applicable to as many people as feasible given the restraints (economic costs, time restraints, etc.) of
conducting such research. It is logistically impossible to include everyone, so researchers rely on statistical
principles to produce robust results that can be extrapolated to the general public.
This method has shown to be a valid research technique over years and years of scientiﬁc and statistical
research, but only if the research sample chosen adequately represents the general population. If the sample
4diﬀers in some relevant manner – for example, if those in the sample metabolize a substance at a diﬀerent
rate than those not in the sample – it would be inappropriate to extrapolate the study’s results to the general
public. It follows in some instances, therefore, that if a group were systematically excluded from research
samples the results of such studies would be inapplicable with respect to that group. Simple statistical
concepts indicate the inappropriateness of using the research ﬁndings on anyone of the excluded population.
But that was precisely the treatment women received from the medical and research communities for many
years – yet that did not prevent the prescription for use in women of drugs tested only on men. This occurred
despite the fact women were not represented in the safety and eﬃcacy studies leading to FDA approval. The
past speciﬁc exclusion of women from medical research, which will be reviewed here, has been thoroughly
documented elsewhere. Instead, the primary focus of this paper is an examination of whether recent attempts
to rectify the mistakes of the past have been eﬀective so that women are fully and adequately represented
in current medical research with respect to prescription drugs.
Speciﬁcally, this paper examines the FDA’s treatment of the role of sex in the drug approval process. Do the
current FDA regulations ensure that approved drugs are safe and eﬀective for both sexes? To attempt to
answer this question, known diﬀerences between men and women, the history of excluding women from med-
ical research, and the FDA’s changing regulations will be reviewed. Additionally, actions to address the lack
of research to support the use of prescription drugs in pediatric patients will be summarized. This provides
a useful contrast as pediatric patients also have been intentionally excluded from the drug approval process,
and concerns about the use of drugs in this subpopulation have risen dramatically in recent years. Unlike
with respect to female patients, however, both the FDA and Congress have acted in signiﬁcant fashions to
5ameliorate the situation. In the ﬁnal section of this paper, the current drug approval process is examined
to determine if recent modiﬁcations have gone far enough to overcome the mistakes and generally accepted
principles of the past.
Many of the issues and concerns expressed in this paper are admittedly equally applicable to other subpopu-
lations, like the elderly, children, or racial minority groups. Perhaps additional reforms in the drug approval
process, like those discussed herein with respect to sex diﬀerences, are necessary to respond their needs, but
such considerations lie beyond the scope of this paper. The decision to limit discussion to sex diﬀerences is
in no way meant to discount the validity of unique needs of currently underserved subpopulations. While it
is possible that drug reactions diﬀer signiﬁcantly among racial groups, for example, it is also possible that
such variances are less extreme than those observed between the sexes. Men and women possess entirely
diﬀerent reproductive systems involving organs not present in the other sex. There is no physical distinction
among racial groups that equals the magnitude of this diﬀerence between the sexes. Perhaps the strongest
analogy can be drawn to the necessity of ensuring the safety and eﬃcacy of prescription drugs for children,
as their bodies diﬀer in signiﬁcant ways from the adult form they eventually will take. The special needs of
children have drawn pubic and congressional attention, leading to a new law designed speciﬁcally to address
loopholes in the process that left children exposed to unacceptable risk.
In short, perhaps widespread testing at the subpopulation level may be necessary, but further evidence is
needed to support such a proposition. It is possible that increased pressure to evaluate sex diﬀerences will
encourage researchers to note reaction diﬀerences among subpopulations like the elderly.
I would also argue that creating and enforcing regulations designed to ensure the safety and eﬃcacy for
speciﬁc minority groups may prove problematic. The FDA would likely experience even more diﬃculty
in devising racial and ethnic categories than those the Census Bureau went through in creating categories
6for its most recent survey. And the lines among groups will continue to blur as the number of interracial
individuals, and the cultural and ethnic combinations they represent, increases.
This paper, therefore, focuses speciﬁcally on the role of sex in the current drug approval process. Has the
FDA done enough to ensure women are fully represented in and protected by the drug approval process?
Terminology: Understanding the Diﬀerence Between “Sex” and “Gender”
It is helpful to begin with a clariﬁcation of the diﬀerence between sex and gender. Although often used
interchangeably, the words “sex” and “gender” have distinct meanings. The Institute of Medicine (“IOM”)
recommends the following deﬁnitions of the terms to clarify and to make consistent the use of the two words.
“Sex” refers to an organism’s status as male or female “...according to reproductive organs and functions
that derive from the chromosomal complement.” “Gender” should be used to “...to refer to a person’s
self-representation as male or female, or how that person is responded to by social institutions on the basis
of the individual’s gender presentation.”3 Under this understanding, gender can function as a continuum,
whereas sex is a binary condition.4
Although it may seem a minute point, it is important to separate these two notions when discussing the role
of sex in the drug approval process. Sex diﬀerences are biological, representing the genetic or physiological
characteristics of being either a man or woman. In contrast, gender reﬂects the social and cultural distinctions
3Id. at 8.
4Id. at 17.
7made based on sex, and how those social constructs impact the individual’s image of self.5 For the sake
of good medicine, it is crucial that researchers are aware of this distinction and do their best to minimize
the role gender plays in science while maximizing their sensitivity to sex diﬀerences. That is, they must
maintain the necessary attention to diﬀerences in sex and how they manifest themselves in drug trials while
also separating cultural or social distinctions between men and women that have no basis in science.
This paper focuses, therefore, on the role of sex in the drug approval process, not that of gender. Gender
most likely also exerts inﬂuence on the drug approval process, but in a more subtle fashion. To protect
both sexes it is important that the process remain faithful to scientiﬁc principles, which in this case means
becoming sensitive to the role sex plays in a human’s reaction to a drug compound.
The Impact of Sex in Variety of Medical Contexts
Before examining the drug approval process in detail, it will be useful to gain an understanding of the
persistent and varied diﬀerences that have thus far been found between men and women. “A striking aspect
of some sex diﬀerences is the consistency with which they appear across populations with vastly diﬀerent
health status proﬁles and environmental circumstances.”6 Adding to this is the presence of sex diﬀerences
in the instances and the symptoms of a variety of diseases, and the often-inexplicable (in light of the current
level of scientiﬁc and biological knowledge) impact sex has on response to treatment.
5Vivian W. Pinn, Sex and Gender Factors in Medical Studies: Implications for Health and Clinical Practice, 289(4) J.
American Medical Ass’n. 397 (2003).
6Committee on Understanding the Biology of Sex and Gender Differences, Institute of Medicine, supra note 1,
at 20.
8Through public awareness campaigns, most Americans have become aware of the symptoms of a heart
attack. Chest pain, shortness of breath, and pain radiating down the left arm motivate many to seek
immediate medical attention. What is less widely known, however, is that these commonly recognized
symptoms of a heart attack are less common in women than in men. It is estimated that about 20% of
female heart attack victims present symptoms that are not recognized, even by trained medical personnel,
as indicators of myocardial infarctions. Instead of the “typical” symptoms, these women experience pain
in the upper abdomen or back, nausea, shortness of breath, and sweating. Doctors sometimes misdiagnose
these “atypical” complaints as indications of an anxiety attack or indigestion. Instead of receiving immediate
medical treatment for their heart attacks, some misdiagnosed women are sent home with prescriptions for
Valium to combat their “anxiety” or with antacids to treat their “indigestion.” One twenty-seven year-old
woman so treated dropped dead in the parking lot after being dismissed from the hospital emergency room.7
Not only do indications of a heart attack sometimes diﬀer by sex, but also the role cholesterol plays as
risk factor depends upon an individual’s sex. Both sexes face increased risks for coronary artery disease
from having high cholesterol, or more speciﬁcally from having a high LDL (low-density lipoprotein) number.
This is commonly referred to as “bad” cholesterol. But women must also carefully watch their level of HDL
(high-density lipoprotein), also known as “good” cholesterol, as their risk for coronary heart disease increases
if this number falls below the normal level. This number may actually be more important for women to
monitor than the more commonly acknowledged risk factor of high bad cholesterol. The National Cholesterol
Education Panel recommends maintaining HDL levels above 45 for both sexes, but other researchers have
suggested that the safe level for women may actually be 70 or higher.8
Even among risk factors that aﬀect both men and women, the degree of risk may diﬀer by sex. Holding
everything else constant, smoking is more likely to lead to lung cancer in women than in men. And lung
7Popular misconceptions about women’s health and emerging trends in medical research transcript, Talk of the Nation,
National Public Radio, Host: Neal Conan (July 30, 2002).
8Id.
9cancer in women is more likely to develop in the periphery of the lungs so that women may experience
symptoms of the cancer at a later stage of the disease than similarly aﬄicted men.9 Obviously this delay in
disease recognition can have a dramatic eﬀect on the likelihood of survival following diagnosis; as a result,
smoking may prove to be more lethal for women than for men.
While the classic symptoms of a heart attack generally match better the experiences of males than females,
those of depression more closely comport with the typical female manifestations of the disease than with those
exhibited by males. While suﬀering from depression, men are more likely than similarly depressed women
to resort to violence or to abuse alcohol. These atypical symptoms often go unrecognized as indications of
the mental health condition, leading many to believe that the incidence of depression is far higher in women
than in men. The percentage aﬄicted in both sexes may, in reality, be closer than previously suspected.10
Other mental health conditions also aﬄict the sexes diﬀerently. While schizophrenia and biopolar disorders
are equally prevalent in men and women, the age at onset of the disease, the pattern of symptoms, and the
response to treatment diﬀer by sex. Autism, learning disabilities, and attention-deﬁcit disorder are more
common in men.11
Instances of diﬀerent reactions by sex continue to come to light in startlingly unexpected situations. Such
incidences highlight the diﬃculty of predicting beforehand which diseases or treatments will result in dif-
ferences, in outcomes or in symptoms, between men and women. For example, researchers in 1992 studied
the eﬀects of a new measles vaccine given to children in Haiti. For some inexplicable reason, girls given the
vaccine exhibited a signiﬁcantly higher mortality rate than that seen among the boys. This occurred despite
the fact researchers found boys received no preferential health care treatment; the researchers were unable
9Id.
10Id.
11Pinn, supra note 5, at 399.
10to cite any biological reason to explain the results.12
The list of sex diﬀerences is quite long. Urinary incontinence, which aﬄicts twice as many women as men,
typically results from diﬀerent causes in each sex. For women, it is commonly caused by deﬁcits of urine
storage associated with risk factors related to the female pelvic anatomy and physiology; for men, urinary
incontinence often results from bladder outlet obstruction.13 Irritable Bowel Syndrome (“IBS”) is three times
more prevalent in women than men.14 Women are more likely to recover language ability after a stroke, as
well as more likely to develop dangerous ventricular arrhythmias in response to potassium channel-blocking
drugs.15 Kappa opiods, which are morphine-like painkillers, oﬀer powerful, long-lasting relief to women,
yet can make pain worse for men at certain doses.16 Two studies suggest that women are less responsive
to anesthesia than men and, as a result, wake up three to four minutes faster after taking same dose of
medication per pound of body weight. In general women also suﬀer more side eﬀects from anesthesia.17
Some studies have shown that “female” kidneys act more slowly than “male” kidneys. Liver function may
also vary by sex.18 As a result of this diﬀerence in liver function, how drugs are metabolized diﬀers between
men and women. This, in turn, may explain in part the diﬀerent reactions seen in men versus women to
certain drugs.19
12Women’s Health Law Symposium, Rutgers School of Law-Newark, 16 Women’s Rts. L. Rep. 17, 30 (1994).
13Pinn, supra note 5, at 398.
14Id.
15Committee on Understanding the Biology of Sex and Gender Differences, Institute of Medicine, supra note 1,
at 19.
16Pharmacology: Study highlights threat of sex discrimination in the medicine cabinet, Medical Letter on the CDC &
FDA, Aug. 25, 2002, at 15.
17Id.
18Id.
19Judith Levine Willis, Equity in Clinical Trials: Drugs and Gender, FDA Consumer Special Report (1997), available at
http://www.fda.gov/oashi/aids/equal.html.
11The purpose behind this laundry list of diﬀerences between men and women is to highlight the signiﬁcant
truth that men and women are diﬀerent in very signiﬁcant respects. This concept is generally understood
on a shallow, almost comical level (e.g., men are from Venus, women are from Mars), yet has deep, profound
implications on an important biological level. When this point is pressed further, men and women obviously
have diﬀerent reproductive organs. And it is also commonly recognized that men, on average, have lower body
fat percentages and more muscle than women of same height and weight. Men usually have more abdominal
fat and less gluteal-femoral fat than women.20 Yet these commonly recognized physical diﬀerences between
the sexes hide deeper and far more signiﬁcant diﬀerences that dramatically impact medical care. To be
eﬀective and reliable, any research that attempts to explain or predict human reactions or diseases must be
sensitive to the distinctions that exist between the sexes.
Sex Diﬀerences in General Medical Research and Treatment
Returning to the above discussion of heart disease, many adults have included aspirin consumption in their
daily regime speciﬁcally to combat heart disease. What many do not know, however, is that the study that
led to this general practice included no women subjects. Amazingly, all 22,071 subjects in that study were
male physicians. Another signiﬁcant study on the relationship between cholesterol and heart disease included
approximately 15,000 subjects, all of whom were male. Yet another study on the role of caﬀeine consumption
in the development of heart disease counted no women among its 45,589 subjects.21 It is entirely possible
that the results of those studies are equally applicable to women and well as men, but they demonstrate the
20Committee on Understanding the Biology of Sex and Gender Differences, Institute of Medicine, supra note 1,
at 131.
21Women’s Health Law Symposium, Rutgers School of Law-Newark, supra note 12, at 19-20.
12focus scientiﬁc research placed on male subjects as the norms.
Many such studies were conducted in earlier times (and seemingly prehistoric times with respect to women’s
rights) when it was widely believed that research conducted with exclusively male subjects could be ex-
trapolated to women with no special consideration for sex diﬀerences. It was generally accepted that what
worked in men would necessarily work in women without any science to support this assertion. The eﬀect
and demise of this common misconception will be discussed below speciﬁcally with respect to prescription
drug research. But some studies, when considered today, simply defy common sense and cannot be explained
with an understanding of the less enlightened perception of sex diﬀerences that existed within the research
community even a few decades ago.
For example, the National Institutes of Health (“NIH”) funded a study on breast and uterine cancer that
included male subjects. While men do suﬀer, albeit at much lower rates, from breast cancer, they obviously
do not have uteruses. The justiﬁcation for the inclusion of male subjects in a study designed to learn about
cancer in an organ males do not have was that the focus of the study was on the eﬀect on estrogen metabolism
of certain nutrients. As it was believed such metabolism was similarly aﬀected in the two sexes, males were
viewed as appropriate subjects of the research.22
In addition to the lack of attention often paid to women’s issues in medical research, in some cases women
receive inadequate medical care as a result of the use of men of average weight as the prototypical patients. As
a result of the focus on stereotypical heart attack symptoms, which also happen to be more representational
of heart attacks in men, heart attacks in women often go undiagnosed and under-treated. Articles in the
22Women Sufficiently Represented in New Drug Testing, but FDA Oversight Needs Improvement, (GAO-01-754,
July, 6, 2001) at 20.
13New England Journal of Medicine have shown that female patients get fewer angiograms, fewer cardiac
revascularizations, fewer cardiac catheterizations, fewer bypass surgeries, fewer balloon angioplasties, and
fewer “clot-buster” drugs.23 In general, doctors are more hesitant to recommend surgery for their female
patients than their male ones. Other studies have shown that men have better access to kidney dialysis and
transplantation, despite the fact that women show better response rates to both courses of treatment.24
Growing Acknowledgement of Diﬀering Drug Reactions by Sex
Given the numerous ways in which men and women diﬀer medically and biologically, only some of which
were discussed above, it is not surprising that similar patterns have been seen with respect to prescription
drugs. As science has become more sensitive to the importance of sex in a variety of medical contexts, many
have begun to question and reevaluate its role in the development and approval of prescription drugs.
At the 62nd Congress of the International Pharmaceutical Federation held August 31 through September 5,
2002 in Nice, France, a program entitled Gender Analysis of Medications: Challenges to the Sciences and
the Profession of Pharmacy was presented. Various speakers repeatedly acknowledged “...the need to go
beyond the ‘70-kg male’ conventional model in clinical studies of medications.”25
One researcher who contributed to the IOM report on sex diﬀerences, Carmen Sapienza, Ph.D., of Temple
23See, e.g., Ayanian J Z, Epstein A M. Diﬀerences in the use of procedures between women and men hospitalized for coronary
heart disease. New England Journal of Medicine, 1991, 325: 221-225; Steingart R M, Packer M, Hamm P, et al., for the Survival
and Ventricular Enlargement Investigators. Sex Diﬀerences in the Management of coronary Heart Disease. New England Journal
of Medicine, 1991. 325: 226-230; Greenberg, Mark A, Mueller, Hiltrud S. Why the Excess Mortality in Women after PTCA?
Vol 87(3), March 1993, 1030-1032.
24Women’s Health Law Symposium, Rutgers School of Law-Newark, supra note 12, at 20.
25Marianne Rollings, How genders diﬀer in their response to drugs; Rx Care, Drug Topics, Oct. 7, 2002, at 129.
14University, attended the Nice conference and reported simply that “[e]very cell has a sex. In her opinion, it
is necessary to study further the diﬀerences between the sexes “from womb to tomb” to ensure that adequate
medical care is being provided for all. She also emphasized that there is a distinction between hormonal
eﬀects and underlying diﬀerences between men and women. And this is a distinction that requires much
further research. In her words, “Until the question of sex is routinely asked, and the results – positive or
negative – routinely reported, many opportunities to better understand the pathogenesis of disease and to
advance human health will surely be missed.”26
The FDA’s Role in the Development of New Drugs
The lack of attention to sex-related diﬀerences throughout medical research was perhaps most pervasive with
respect to drug development. For years, women were explicitly excluded from drug trials as subjects because
researchers and the FDA wanted to prevent the exploitation of women and mistakenly assumed that their
inclusion would represent an unnecessary risk and, potentially, an excessive expense.
The FDA plays a crucial role in the development of any drug within this country (and has a tremendous
impact on the development of drugs around the world). Before a drug sponsor can test on human subjects,
it must submit an investigational new drug application (IND) to the FDA. The IND includes a summary
of prior research, which typically includes cellular and animal research, and a general outline of how human
studies will be performed. Also included are assurances from the drug sponsors to the FDA that they
will do what is necessary to protect the human subjects who may participate in future envisioned trials.
“Speciﬁcally, the IND application demonstrates that the drug is reasonably safe for subsequent testing in
26Id.
15humans based on laboratory and animal testing and exhibits enough potential eﬀectiveness to justify its
commercial development.” Testing can begin thirty-one days after submission unless the FDA ﬁnds that the
proposed study is somehow unsafe or it ﬁnds some signiﬁcant ﬂaw with the submitted IND application.27
Following the submission of an unchallenged IND, clinical drug testing of the particular compound proceeds
in three stages. Phase I consists of small-scale safety trials, usually using healthy volunteers to ascertain safe
dosing levels and to determine toxicity. At this stage the substance’s “pharmacokinetics,” “the time course
of the drug’s absorption, distribution, metabolism (biotransformation), and excretion”28, are also evaluated
in addition to the dose response. Small-scale eﬃcacy trials commence in Phase II, typically employing the
use of a control group to determine the drug’s eﬀectiveness and to monitor for any side eﬀects or adverse
reactions. It is in Phase III that full-scale safety and eﬃcacy trials are conducted. A large number of subjects
is pooled together to further the research aims begun in Phase II. During clinical trials, sponsors must submit
annual IND reports to the FDA, and this overall process of clinical testing usually spans from, on average,
two to ten years.29 Assuming the results of Phase III are favorable, a drug sponsor then submits a New
Drug Application (“NDA”) as the last major step prior to obtaining approval to market its substance.
“
Through this mechanism [IND application and process], which is designed to protect human subjects, and
its GLP (good laboratory practices) regulations, the FDA exerts considerable control over the conduct of
27Women Sufficiently Represented in New Drug Testing, but FDA Oversight Needs Improvement, supra note 22,
at 6.
28Committee on Understanding the Biology of Sex and Gender Differences, Institute of Medicine, supra note 1,
at 118.
29Women Sufficiently Represented in New Drug Testing, but FDA Oversight Needs Improvement, supra note 22,
at 6.
16clinical trials.” Before the 1962 amendments to its statute, the FDA’s involvement began much later in the
investigational process when a sponsor would submit an application to market an already tested product.30
Now, the FDA plays a crucial role in designing the clinical drug trials involving human subjects necessary to
support its approval for sale in this country. It also exercises signiﬁcant control over drug labeling, including
information related to indications for use and determining the populations for which the substance has been
shown safe and eﬀective.31 But once a drug is approved, the use of the substance by a doctor is unregulated
by the FDA, though the agency does maintain control over the drug’s marketing. The regulations permit
physicians to use an approved drug for people and for conditions not speciﬁed by the product label, and this
practice is referred to as “oﬀ-label use.”32
A History of Excluding Women from Drug Trials
The basis for the current IND procedures is found in the 1962 amendments to the Federal Food, Drug, and
Cosmetic Act that established the present drug approval process. Passage of the amendments was motivated
by the thalidomide-related birth defects tragedy.33 While the motivating tragedy obviously involved the
consumption of drugs by women, Congress did not press for the equal treatment of women in the drug
approval process. In fact, social forces and ethical concerns pushed the FDA and Congress in the opposite
direction.
30Robert Higgs (ed.), Hazardous to our Health? FDA Regulation of Health Care Products 16
(The Independent Institute, 1995).
31Women Sufficiently Represented in New Drug Testing, but FDA Oversight Needs Improvement, supra note 22,
at 5.
32Marilynn C. Frederiksen, The Drug Development Process and the Pregnant Woman, 47 J. Midwifery & Women’s Health
422, 423 (Nov./Dec. 2002).
33Women’s Health Law Symposium, Rutgers School of Law-Newark, supra note 12, at 25.
17The ethical issues implicated by medical research received heightened attention following the Nuremberg
War Crime Trials after World War II. The judicial process revealed atrocities perpetrated by the Nazis,
under the disguise of scientiﬁc inquiry, on Jews and other groups considered “undesirable.” This knowledge
elevated public concern, awareness, and sensitivity around the world regarding the use of human subjects in
the name of science.34
The Nuremberg Code of Ethics of 1949 outlined basic moral, ethical, and legal requirements of using human
subjects in research. This inﬂuenced the growth of a protectionist policy with respect to human subjects
within the U.S. federal government. The Tuskegee syphilis study provided a domestic example of the ex-
ploitation of a marginalized group for the supposed advancement of science. These ethical abuses colored
perception of the thalidomide tragedy so that it was viewed as additional evidence of the need to protect
women from the sometimes-unscrupulous scientiﬁc community.35 Such factors, in conjunction with the male-
centric view of society that dominated contemporary thinking, led to the formal exclusion of women subjects
from drug trials.
In response to research abuse concerns and the desire to formalize the drug approval process, the “Federal
Policy for the Protection of Human Subjects” (45 C.F.R. §§ 46.101 – 46.124) was promulgated in 1974. The
policy included language promoting the notion of “equitable” subject selection,36 but this did not mean
that researchers were to ensure that all had equal access to study participation. Rather, its goals reﬂected
concerns about the potential for research abuses that arose from the experiences at Nuremberg. The authors
of the government policy sought to prevent the exploitation of one group for the beneﬁt of another, e.g., the
use of public patients as test subjects for the beneﬁt of private patients.37
34Id.
35Committee on Understanding the Biology of Sex and Gender Differences, Institute of Medicine, supra note 1,
at 24.
3645 C.F.R. § 46.111(a)(3).
37Women’s Health Law Symposium, Rutgers School of Law-Newark, supra note 12, at 26.
18In addition to this overall desire to protect vulnerable minorities from exploitation by the majority (or
the politically/socially weak and the politically/socially powerful, respectfully), the Federal Policy for the
Protection of Human Subjects mentions speciﬁc populations warranting additional protection from potential
ethical abuses. 45 C.F.R. § 46.111 reads in part: “When some or all of the subjects are likely to be vulnerable
to coercion or undue inﬂuence, such as children, prisoners, pregnant women, mentally disabled persons, or
economically or educationally disadvantaged persons, additional safeguards have been included in the study
to protect the rights and welfare of these subjects.”38 This language may startle the modern reader for its
grouping of women, pregnant or not, with obviously and undeniably vulnerable populations like children or
mentally disabled people. But it is interesting to note that women at the time were not so oﬀended because
their worries focused on the danger of being exploited by research. As a result, they did not mind being
excluded from it and, in fact, welcomed the protection.39
A 1977 FDA guideline entitled “General Considerations for the Clinical Evaluation of Drugs”40 explicitly
limited, to the point of exclusion, the participation of women of childbearing age in drug research. The term
“childbearing” was broadly deﬁned (essentially all menstruating women were deemed of childbearing age41)
so that almost all women were eﬀectively eliminated from the pool of possible study subjects. Under this
1977 guideline, women could participate only in phase III of the clinical drug trial process. As discussed in
an above section, this eliminated women from the study during the phases (phases I and II) when signiﬁ-
cant information about the drug’s pharmacokinetics is discerned. Despite the FDA’s approval of the use of
female subjects in the ﬁnal phase of drug testing, many drug sponsors opted to remain with an exclusively
male sample throughout the entire study due to the liability concerns. Many sponsors feared a potential
3845 C.F.R. § 46.111(b).
39Women’s Health Law Symposium, Rutgers School of Law-Newark, supra note 12, at 26.
40HEW Publication No. (FDA) 77-3040. (HEW was the Department of Health, Education, and Welfare; it was renamed the
Department of Health and Human Services in 1980 following the creation of Department of Education.)
41Women’s Health Law Symposium, Rutgers School of Law-Newark, supra note 12, at 27.
19thalidomide-like disaster and the ensuing legal, political, and economic damages that could result.42
Scientists oﬀered two basic reasons to justify the exclusion of women from their research studies. One
argument was that menstruation would complicate their research methodology and evaluation of results,
thereby increasing the expense of conducting the work. The second argument focused on potential harms
to fetuses should women become pregnant during the course of the study. 43 All were wary of the potential
public relations and political disaster should the participation in a drug trial by any woman be linked
to the deformities of a child born to her. The science of the day did not recognize the pharmacological
diﬀerences between men and women, so the potential harms of including women as study subjects appeared
to overwhelmingly outweigh any perceived beneﬁt.
“Critics of these 1977 guideline have suggested the policy is more a reﬂection of gender stereotypes, female
susceptibility and male invulnerability, than of sound scientiﬁc considerations.”44 Regardless of what truly
motivated the eﬀective prohibition of women from drug research as study participants, the articulated
justiﬁcations do not make sense and are inconsistent. Researchers were saying both that the hormonal
ﬂuctuations associated with the menstrual cycle might aﬀect the response seen in female subjects and that
results generated from an exclusively male sample were an appropriate basis from which to determine safety
and eﬃcacy levels in women, as well as appropriate dosage. 45 The two positions conﬂict with each other.
The second argument focuses exclusively on potential harms to a fetus through maternal exposure, completely
discounting the ability of men to pass damage resulting from dangerous substances on to their oﬀspring. 46
42Women Sufficiently Represented in New Drug Testing, but FDA Oversight Needs Improvement, supra note 22,
at 26.
43Women’s Health Law Symposium, Rutgers School of Law-Newark, supra note 12, at 20.
44Id. at 27.
45Committee on Understanding the Biology of Sex and Gender Differences, Institute of Medicine, supra note 1,
at 25.
46Women’s Health Law Symposium, Rutgers School of Law-Newark, supra note 12, at 21.
20Consequently, for a number of years the medical community had no sound scientiﬁc basis to justify their
prescription of almost all drugs to their female patients. Society’s general desire to protect women, the
increased attention to ethical abuses in research following the Nazi experience, and an emphasis on women
as mothers (as opposed to a lack of regard for men as fathers) all combined to encourage the FDA to generate
an explicit policy of excluding women from crucial stages of drug research.
Emerging Acknowledgement of the Need for Female Study Subjects in the Drug Approval Process
Because ethical concerns led to the exclusion of women from much of scientiﬁc research, “...the medical com-
munity lacks useful, comparable data on conditions that occur disproportionately, that manifest diﬀerently,
or that require diﬀerent approaches to diagnosis and treatment in males and females.”47 This ignorance of
the female experience, until recently, pervaded the drug approval process.
At the 62nd Congress of the International Pharmaceutical Federation researchers articulated and explained
the need for pharmacokinetic studies and pharmacodynamics on female subjects during phase I and phase
II of clinical drug studies, which had been extremely limited under the FDA’s 1977 guideline with respect
to menstruating women. It is in these two phases that sex diﬀerences in metabolism or other processes will
be most evident because researchers customarily adjust dosages and study the metabolism of the studied
substances at this point in the process. As the dosages evaluated in the ﬁnal stage are established in the
course of phase I and phase II research, it is crucial to allow for the accounting of variations between the
sexes, such as the eﬀects of menstrual cycles, menopause, or the lower rate of metabolism generally seen in
47Committee on Understanding the Biology of Sex and Gender Differences, Institute of Medicine, supra note 1,
at 22-3.
21women.48
The IOM’s Committee on Understanding the Biology of Sex and Gender Diﬀerences published a report enti-
tled “Exploring the Biological Contributions to Human Health: Does Sex Matter?” in 2001. In addition to
answering the question posed in the title with an emphatic “yes,” the report stressed the need to ensure the
equitable treatment of both sexes during medical research. The following quotation summarizes the report’s
ﬁndings:
Being male or female is an important basic human variable that aﬀects health and illness throughout
the life span. Diﬀerences in health and illness are inﬂuenced by individual genetic and physiological
constitutions, as well as by an individual’s interaction with environmental and experiential factors.
The incidence and severity of diseases vary between the sexes and may be related to diﬀerences in
exposures, routes of entry and the processing of a foreign agent, and cellular responses. Although in
many cases these sex diﬀerences can be traced to the direct or indirect eﬀects of hormones associated
with reproduction, diﬀerences cannot be solely attributed to hormones. Therefore, sex should be
considered when designing and analyzing studies in all areas and at all levels of biomedical and
health-related research.49
The need to infuse each stage of the drug approval process with sensitivity for possible variations by sex is
heightened by the examples discussed in the earlier sections of this paper. Many of the sex diﬀerences have
nothing to do with the obvious diﬀerences in anatomy between men and women. In the case of the Haitian
vaccine study, for example, researchers were unable to determine an explanation for the higher mortality
rates among the female recipients. A few years ago it would have seemed almost ridiculous to think of a
kidney as being either male or female, but science has shown that sex has signiﬁcant impacts at a variety of
levels, even at the molecular level. As many sex diﬀerences appear startling ex post, it is crucial to design
the drug approval process ex ante so that such diﬀerences are noted as early in the process as possible so
that an approved drug is truly safe and eﬀective for women and men.
48Rollings, supra note 25.
22FDA’s Changing Policy Statements and Guidelines Regarding Women as Study Subjects
The FDA has made signiﬁcant advances in recognizing the importance of including female subjects since the
days of essentially excluding their presence in all but the ﬁnal stage of clinical drug trials. The rest of this
paper will evaluate the eﬀectiveness of these policy changes to determine if the current approach the FDA
employs is suﬃcient to fulﬁll its mission of ensuring that only safe and eﬀective, for both men and women,
drugs reach the market.
The FDA formally reversed its 1977 policy with respect to menstruating women in 1993, noting “fetal protec-
tion can be achieved by measures short of excluding women from early trials.”50 This guidance, “Guideline
for the Study and Evaluation of Gender Diﬀerences in the Clinical Evaluation of Drugs,” was published in
the Federal Register on July 22, 1993.51 A variety of factors culminated in this policy shift. Obviously the
changing role of women in society played a role. As the baby-boomers hit middle age, the women of this
cohort group began taking more active roles in their health as their bodies aged and they became more
demanding medical care consumers. Their experiences increased awareness of the dearth of information
about women due to past research practices designed to protect women from exploitation. In addition, the
notion of patient autonomy, so that patients now expect to play a role in making medical treatment decisions
instead of deferring automatically to their physicians’ authority, expanded in this country.52 These factors
combined to create a largely grassroots eﬀort to acknowledge sex diﬀerences from a medical standpoint and
to encourage researchers to include females in the sample groups studied.53
As the Nuremberg War Crime Trials and the thalidomide tragedy shaped public perception medical research
in their times, the growing AIDS crisis of the 1980s signiﬁcantly impacted the public’s opinions of such
50Women Sufficiently Represented in New Drug Testing, but FDA Oversight Needs Improvement, supra note 22,
at 27.
5158 Fed. Reg. 39,406 (July 22, 1993).
52Women’s Health Law Symposium, Rutgers School of Law-Newark, supra note 12, at 28.
53Popular misconceptions about women’s health and emerging trends in medical research, supra note 7.
23research. No longer viewed as a threat, research was re-characterized as a public good worthy of increased
government and private funding and support. Early AIDS activists of the ‘80s worried more about the
dangers, in the form of lives lost, of slow or inadequate research, than about the potential exploitation of
vulnerable groups that had shaped government policy decades before.54 Activists fought for expanded access
in the earliest stages of clinical research. This is big shift from when women welcomed the protection aﬀorded
to them by the FDA’s policy of excluding women from early drug research.
The FDA studied the rate of female inclusion in samples used in clinical drug trials from 1983 to 1989. It
found the proportions of the sexes roughly approximated that seen in the incidence of disease for which the
drug was being developed once the age range of the population being studied was accounted for.55 While
the sex of the sample generally matched the sex of those aﬄicted with the given condition, this did not mean
there was necessarily enough in either group to show, with statistical suﬃciency, the substance safe for either
gender. The seemingly positive indication of the report of a growing inclusion of women is further limited by
the fact the FDA could not determine the gender of more than one half of participants in submitted annual
IND reports.56
Another report, this one authored by the General Accounting Oﬃce (“GAO”), examined drug sponsors’
deliberate attention to the inclusion of women and the sponsors’ interaction with the FDA with respect to
this issue. The October 1992 report contained a summary of surveyed drug manufacturers that obtained
FDA approval between January 1988 and June 1991. Overall, the survey response rate was 92%.57 One
quarter of the respondents indicated that they did not deliberately recruit women to serve as subjects in
study in numbers designed to match their proportion of the subject disease or condition’s population. One
54Women’s Health Law Symposium, Rutgers School of Law-Newark, supra note 12, at 28.
55Investigational New Drug Applications and New Drug Applications, 21 CFR §§ 312, 314 (1998).
56Women Sufficiently Represented in New Drug Testing, but FDA Oversight Needs Improvement, supra note 22,
at 9-10.
57Women’s Health: FDA Needs to Ensure More Study of Gender Differences in Prescription Drug Testing,
(GAO/HRD-93-17, October 1992) at 19.
24half reported that the FDA had asked that women be included in their trials, while the other half said had
not been asked.58
This 1992 GAO report raised serious concerns about the ability of the drug approval process to determine
safety and eﬃcacy for women. Unlike the FDA’s own study discussed above, the GAO reported that women
were generally underrepresented, meaning fewer women participated in studies, as a proportion, than were
found in intended population of users.59 Most of the reviewed studies had at least 250 female participants,
which was the FDA suggested minimum number, but a full one third included fewer than 250 women.60
Many of the responding drug manufacturers admitted that they did not study if the drug in question in-
teracted with female hormones, including those commonly found in oral contraceptives.61 The report noted
that approximately one quarter of childbearing age women use oral contraceptives, and that it is known
certain epilepsy drugs can diminish their eﬀectiveness and some antidepressants can increase their eﬀect on
the body to the point of toxicity.62
After reviewing the status of sex awareness in the drug approval process, the GAO made several suggestions.
It asserted that manufacturers should consider the interplay between their drugs and oral contraceptives,
despite the fact the FDA’s regulations did not require this investigation.63 As to the FDA, the GAO rec-
ommended the Commissioner issue guidance to instruct drug sponsors as to the necessary level of inclusion
for both sexes to determine statistical safety and eﬃcacy for men and women. According to this 1992 GAO
report, the FDA should also require that drug manufacturers analyze the results of drug studies by sex.64
The July 1993 guidance, revising the section of the 1977 guideline that excluded women of childbearing






63Women’s Health: FDA Needs to Ensure More Study of Gender Differences in Prescription Drug Testing,
supra note 57, at 12.
64Id. at 13. [Source 14, 13]
25between menstrual cycle, menopause, and oral contraceptives and drugs. In this document the FDA also
recognizes the earlier exclusionary policy seemed “rigid and paternalistic” when viewed from the more in-
clusive perspective of the 1990s.65 “The early exclusion also may have perpetuated, in a subtle way, a view
of the male as the primary focus of medicine and drug development,”66 according to the FDA, though the
subtlety of this policy is debatable.
In contrast to early justiﬁcations for male-only samples focusing on potential risks to fetuses, the 1993 guid-
ance acknowledges women’s right to determine what risk, if any, is appropriate for their bodies and their
fetuses. The FDA cited a Supreme Court decision67 forbidding the exclusion of pregnant women from cer-
tain jobs due to risk and noted the parallel to the their own exclusionary policies.68 This guidance directly
confronted and rebutted the two articulated reasons for excluding women from medical research. To maxi-
mize its scientiﬁc value, research needs to evaluate the eﬀect of ﬂuctuating hormones due to menstruating,
menopause, and use of birth control pills, regardless of the increased study costs. And it was no longer seen
as the government’s or the research community’s responsibility to protect fetuses from potential exposure.
Instead, this task fell to the potential mother in question.
Yet there was a signiﬁcant limit to how far the FDA was willing to go to ensure women had equal access to
clinical drug trials. The FDA demonstrated an important shift in thinking with respect to the previously
articulated reasons for dramatically limiting female participation in research, but it did not wish to addresses
the biases now inherent to the process as a result of its previous policy. The FDA concluded that there was
no “...regulatory basis for requiring routinely that women in general or women of childbearing potential be
included in particular trials, such as phase I studies.”69 This statement was made despite its own growing
65Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs, 58 Fed.
Reg. 39,406 (proposed July 22, 1993).
66Id. at 39,408.
67International Union, United Automobile, Aerospace, and Agricultural Implement Workers, UAW v. Johnson Controls,
Inc., 111 S. Ct. 1196 (1991).
68Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs, supra
note 63, at 39408.
69Id.
26appreciation for the sometimes-signiﬁcant diﬀerences between men and women when using the same drug.
The guidance issued in 1993 merely recommended the inclusion of men and women “in number adequate
to allow the detection of clinically signiﬁcant gender diﬀerences in drug response.” Just as the GAO did in
its 1992 report, the FDA suggested drug manufacturers include data analysis of safety and eﬃcacy by sex
in NDAs.70 But there remains no regulation requiring the inclusion of women at a rate suﬃcient to yield
statistically signiﬁcant results to support a ﬁnding that the substance in question is safe and eﬀective for
women patients. In practice, the male study subject has remained the default.
Congress passed the FDA Modernization Act in 1997. One provision of the act amended 21 U.S.C. 355(b)(1)
to include the following: “The Secretary shall, in consultation with the Director of the National Institutes
of Health and with representatives of the drug manufacturing industry, review and develop guidance, as
appropriate, on the inclusion of women and minorities in clinical trials.”71 The FDAMA Women and Mi-
norities Working Group Report was charged with ensuring compliance with Congress’s explicit instructions.
The Group’s ﬁrst step consisted of a review of existing regulations to see if they adequately responded to
the needs of women and minorities by ensuring their proper representation in the studies conducted in the
course of the drug approval process. In the alternative, the Group could have found that it lacked suﬃcient
information to make such a determination.72
The Working Group’s review of the then existing FDA guidance began with the 1988 “Guideline for the For-
mat and Content of Clinical and Statistical Sections of New Drug Applications,” which emphasized need for
analysis of demographic information in NDAs. The review concluded with the then-recent 1998 regulation,
“Final Rule on Investigation New Drug Applications and New Drug Applications,” requiring breakdown of
eﬀectiveness and safety data by subgroups, including gender and racial groups. The Group highlighted the
70Women Sufficiently Represented in New Drug Testing, but FDA Oversight Needs Improvement, supra note 22,
at 10.
71Michael A. Friedman, FDAMA – Women and Minorities Guidance Requirements (1998) available at
http://www.fda.gov/cder/guidance/women.pdf.
72Id. at 1.
27fact the FDA possessed the authority to refuse to ﬁle an NDA should the manufacturer fail to tabulate the
necessary information by sex. It then referred back to the 1993 guidance that emphasized the need for sex
considerations in drug research.73
With respect to women, the FDAMA Working Group concluded the following:
In the last ﬁve years, FDA has issued critical guidance and regulation aimed at ensuring
that women are included appropriately in clinical trials and that data are analyzed to
ensure that gender information is available and understood. At present, FDA believes
that exclusionary policies regarding the participation of women with childbearing potential in clinical
trials will be addressed by the 1998 clinical hold proposed rule, if it is ﬁnalized. Therefore, additional
guidance is not indicated, and would not be useful, at this time.74
Based on such recommendations, the FDA concluded no additional guidance was required to satisfy the
amendments of the Modernization Act in this regard. In the Group’s opinion, the regulations in place
suﬃciently protected the needs of subpopulations, so that the drug approval process protected the drug’s
intended population.
The 1998 rule the Working Group cited in arguing for the adequacy of current FDA handling of sex diﬀerences
mandates the content and format of NDAs. It requires the drug sponsor to break down the safety and
eﬀectiveness data into various demographic subgroups “...including age group, gender, and race, and when
appropriate, other subgroups of the population of patients treated, such as patients with renal failure, or
patients with diﬀerent severity levels of the disease.”75 This followed the FDA’s ﬁrst formal encouragement
of such analysis by subgroups in 1995 to support dosage modiﬁcations for certain populations, like pediatrics,
geriatrics, or patients with renal failure.76
The FDAMA Working Group did suggest the creation of a tracking system to monitor submission of racial
73Id. at 2.
75Investigational New Drug Applications and New Drug Applications, 21 C.F.R. §§ 312 et seq., 314 et seq. (1998).
76Id.
28and gender information and the development of “...a program to educate reviewers on the new rule.”77
The hope was that such a system would act as a further safeguard to ensure the needs of subpopulations,
including women, would remain a critical component of the overall drug approval process. As will be seen in
the discussion appearing below, these suggestions were not followed, and it can be argued that the FDAMA
Working Group was overly optimistic in ﬁnding the system suﬃcient to address the needs of women.
Signiﬁcant Sex Diﬀerences Found in a Study of Recently Withdrawn Prescription Drugs
Despite the FDA’s determination that existing guidance and regulations provide suﬃcient safeguards to
ensure approved drugs are appropriate for both sexes, subsequent events raise questions as to the validity of
this belief. There is some signiﬁcant evidence that the drug approval process as it currently functions does
not adequately consider the importance of sex, thereby subjecting female patients to an unacceptable and
unnecessary level of risk.
In response to a congressional request, the GAO submitted a report dated January 19, 2001 reviewing the
drug products withdrawn from the market after obtaining approval from the FDA since January 1, 1997.
It is signiﬁcant to note that the drugs were approved almost four years after the FDA formally reversed its
policy regarding the inclusion of women in drug trials. The speciﬁc focus of the report was to ascertain if
any of the withdrawn product posed a higher degree of risk to women than to men. The GAO collected
information from publicly available documents, including FDA documents and review of medical literature,
and conferred with drug safety experts. The report’s ﬁndings were conﬁned to prescription drugs, and the
GAO did not review the rate of adverse events related to over-the-counter drugs or vaccines. The GAO
77Friedman, supra note 71, at 3.
29conducted its work from December 2000 to January 2001. 78
The GAO found that ten prescription drugs were removed from market during the time period studied. Of
the ten, four led to more adverse events in women than in men despite being equally prescribed to both
sexes. Four other prescription drugs were associated with more adverse reactions in women than in men,
but this likely occurred, at least in part, because more women than men consumed them. The report went
on: “Of the two remaining withdrawn drugs, one belongs to a class of drugs known to pose a greater health
risk for women, but we were unable to ﬁnd direct evidence that the adverse events that contributed to its
withdrawal occurred predominantly in women.”79 Only one of the ten withdrawn prescription drugs did not
demonstrate a greater degree of harm in any way for women as compared to men.
The four drugs shown to be more dangerous to women than men were: Seldane (antihistamine); Posicor
(cardiovascular); Hismanal (antihistamine); and Propulsid (gastro-intestinal). The following four led to
a greater number of adverse events in women than men due to the diﬀerences in prescription rates by
sex: Pondimin (appetite suppressant); Redux (appetite suppressant); Rezulin (diabetic); and Lotronex
(gastrointestinal). Propulsid is still available, minimally, on a patient-by-patient basis for those with severely
debilitating diseases (e.g., IBS).80
It is interesting to note that the time period of this GAO report overlaps with that of the work done by
the FDAMA Working Group. When the GAO examined the practical eﬀects of the FDA’s drug approval
process, it found some startling results not reﬂected in the Working Group’s report. That report instead
focused on the drug approval process in the abstract. The two approaches led to very diﬀerent results,




30and together they show that while the drug approval process may theoretically be unbiased, it may subject
women to an unacceptable higher degree of risk than similarly situated men.
It was impossible for the GAO to determine in its review the exact cause of the disproportionate eﬀect of
some of the drugs removed from the market. It is entirely possible that real problem was a lack of adjustment
in the dosage to account for the lower body weight, on average, of women as compared to men. It is also
possible there was a more fundamental, sex-related distinction between men and women that interacted with
the prescription drug, so that what was an eﬀective, appropriate substance for use in men was not so for
women. But what caused the diﬀering adverse reactions in the two sexes is not the real point. The real point
is that the drug approval process, designed to catch potential issues relating to the use of a drug before that
drug is widely available on the market, did not work for women. And this was a relatively small study over
a restricted period time. It is quite possible the problem is far more pervasive than this study suggests, with
more women suﬀering from a higher rate of side eﬀects or inadequate relief from the use of a drug shown to
be safe and eﬀective essentially only for men.
Loopholes in the FDA’s Current Approach and the Drug Approval Process
No one would argue that the FDA is intentionally subjecting women to additional risk as compared to men.
But the question remains: How could the drug approval process seem responsive to sex diﬀerences yet yield
signiﬁcantly diﬀerent and adverse results for women?81
81See, e.g., P. Greenberger, News from the Society for Women’s Health Research: FDA doing poor job of monitoring drugs
for sex diﬀerences, 10 J Womens Health Gend Based Med 829 (Nov. 2001).
31To answer this question, it is ﬁrst necessary to understand a bit about administrative law. Regulations
have force of law, while a guidance does not bind the FDA or drug manufacturers. A guidance is intended
to show how, according the to FDA’s current opinion on the status of the relevant laws, statutory and
regulatory requirements may be met – but drug sponsors remain free to choose another method to fulﬁll the
prerequisites of market approval. When the guidance on a particular topic is issued before regulation, the
FDA applies the earlier guidance in manner consistent with later regulation.82
Crucial diﬀerences exist between the 1993 guidance and the 1998 regulation discussed above. As the GAO
summarized:
The 1993 guidance speciﬁcally discusses the need to analyze clinical data by sex, evaluate potential
sex diﬀerences in pharmacokinetics, including those caused by body weight, and conduct speciﬁc
additional studies in women, where clinically indicated. The 1998 regulation requires the presenta-
tion of safety and eﬃcacy data already collected in the NDA by sex, but no analysis of such data
is required. The regulation does not include a standard for the inclusion of women; it requires only
‘presentation of data’ without clarifying the extent of data or the format to be used. The regulation
does require the identiﬁcation of any modiﬁcations in dose or dose interval because of sex, age, or
race, but not weight.83
In other words, the 1998 regulation is much less speciﬁc, as it largely discusses how to present the existing
and already included information and does not require analysis of data. It does, however, require tabulation
of that data by sex in the required annual IND reports.84 The 1993 guidance speaks of the importance
of analyzing study data to highlight potential diﬀerences in drug reactions between the sexes. In order to
eﬀectuate this, researchers would have to include enough women so that the results would have any statistical
validity. Had the spirit of this guidance had the force of a regulation, so that drug sponsors would have to
present pharmacokinetic data speciﬁc to women, it would have served as an indirect way of mandating a
suﬃcient proportion of female test subjects, as that would be the only way to produce the requisite data.
Instead, the regulation the FDA promulgated ﬁve years after the guidance was far weaker. On its face it
82Women Sufficiently Represented in New Drug Testing, but FDA Oversight Needs Improvement, supra note 22,
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32may seem to address the issue of the historical exclusion of women from drug trials, but in reality it does
little to mitigate the lingering inequity. The FDA moved subtly from expressing concerns over the lack
of women-speciﬁc, statistically signiﬁcant data to a position of merely delineating the proper format for
expressing the same male-dominated data.
This is not to say that the language contained in the 1993 guidance, had it had the eﬀect of law, would
have done much to ameliorate the situation. But the 1993 guidance does express an acknowledgement of a
problem. When the FDA formally confronted that very same problem ﬁve years later, it did little to address
the true underlying issue – that women are under-represented in study samples – and instead focused on the
presentation of data. It is a cosmetic regulation that has little eﬀect on the substance or design of clinical
drug trials, and instead focuses on the organization of the data, which remains lacking in a very fundamental
regard. That presentation has little value if there are not enough women so that the data analyses by sex
have any statistical or scientiﬁc relevance.
In 1998 Final Rule, the FDA acknowledges “(1) Diﬀerent subgroups of the population may respond diﬀerently
to a speciﬁc drug product and (2) although the eﬀort should be made to look for diﬀerences in eﬀectiveness
and adverse reactions among such subgroups that eﬀort is not being made consistently.” Yet the FDA did
not take the further step of requiring constant analysis throughout the process that would help to enable
sponsors to detect reactions by subpopulations early in the process. The current drug approval process does
not require additional studies or the collection of additional data. As a result, drug sponsors do not have
to ensure that subpopulations, such as women, are adequately represented in the main trails conducted for
FDA approval or have to conduct additional trails to speciﬁcally focus on the safety and eﬀectiveness of the
compound in subsets of the population.
It would obviously be much more cost and time eﬃcient to provide for adequate representation (such that
33the results by subpopulation would be statistically reliable) within the current drug approval process rather
than to require additional studies above and beyond that which the system presently mandates. But the drug
approval process does not mandate the inclusion of a given number of subjects from various subgroups, but
merely covers how already collected data should be presented. So under the 1998 regulation, the additional
“burden” imposed on drug sponsored consisted of tabulating the data by subgroups. Drug sponsors do not
have to ensure that the sample includes enough of each group to generate statistically signiﬁcant results.85
The 1998 regulation changed the form of the data, but did not confront the real problem, which can only be
addressed by a change in the substance of the data.86
One comment submitted to the FDA when this regulation was proposed characterized it as an “empty
gesture.” As it fails to mandate a suﬃcient number of each subgroup population, the regulation would do
nothing to correct problem of insuﬃcient information on the eﬀects of drugs on women. The FDA responded
to the comment in the ﬁnal draft of the regulation with the following:
The agency believes that all of these comments reﬂect a misunderstanding of the intent and scope
of the proposed amendments. This rule does not require any change in the number of studies a drug
sponsor needs to conduct, nor does it impose any new requirements on the conduct of those studies.
The rule refers only to the presentation of data that already has been collected.87
In this response, the FDA acknowledges that the regulation will not ameliorate the underlying problem,
the one which it itself cited when it noted that subgroups are not being studied in a consistent manner.
Overall, the approach taken in the 1998 regulation is decidedly hands oﬀ: “During the past decade, FDA
85Investigational New Drug Applications and New Drug Applications, 21 C.F.R. §§ 312 et seq., 314 et seq. (1998).
86See also K. Ramasubbu & D. Litaker, Gender Bias in Clinical Trials: Do Double Standards Still Apply?, 10 J. of Women’s
Health & Gender-Based Medicine 757, 760, 762 (Oct. 2001) (Reviewed articles published in the New England Journal of
Medicine from 1994 to 1999. Of the 442 randomized, controlled trials discussed therein, 120 met inclusion criteria. On average,
24.6% women were enrolled; gender-speciﬁc data was performed in 14% of trials. Authors concluded that the NIH Revitalization
Act of 1993 “...does not appear to have improved gender-balanced enrollment or promoted the use of gender-speciﬁc analyses
in clinical trials published in an inﬂuential medical journal. Overcoming this trend will require rigorous eﬀorts on the part of
funding entities, trial investigators, and journals disseminating study results.” In fact, ﬁve trials explicitly excluded women of
child-bearing potential without providing a rationale for the decision. According to the authors, “[t]his study adds to already
ample evidence that amended clinical trial guidelines have had little eﬀect on improving the scientiﬁc basis of medical practice
for women.”)
34has encouraged demographic subgroup analyses in various guidance documents and other regulatory actions.
FDA also has examined the extent of participation of past subgroups in drug development programs.”88 But
this appears to be as far as the FDA is willing to go.
With any proposal to alter the drug approval process, the FDA must walk a ﬁne line between ensuring safety
and allowing much needed medications reach those in need. The requirements of the already-lengthy approval
process should not be intensiﬁed without substantial justiﬁcation. The FDA has repeatedly demonstrated
an understandable reluctance to adopt regulations formally requiring the inclusion of female subjects due to
concerns that such a move would delay the overall approval process and result in higher costs to sponsors,
which in turn would harm patients.
What is missing from this understandable position, however, is some substantiation for these fears. Would it
be more costly to include more female study subjects? Why? It would obviously be prohibitively expensive
to require drug manufacturers to conduct trials speciﬁcally designed to screen for potential adverse reactions
in women and to evaluate the safety and eﬀectiveness in women alone. But this is not an automatic necessity.
Instead, it is possible that women could take the place of some of the men currently participating in the
studies. As long as both sexes are suﬃciently represented so that the results are statistically robust, the
drug trial outcomes will be more applicable to all adults than they are currently.
An article published in the Journal of Women’s Health and Gender-Based Medicine reviewed the participa-
tion of women in studies discussed in the New England Journal of Medicine from 1993 to 1999. Among the
120 controlled trials that composed the sample, only 24.6% of the subjects were women. The authors found
the result especially troubling in light of the general understanding and common acceptance of the role of
sex diﬀerences during the time studied. The authors also questioned the willingness of a prestigious medical
88Investigational New Drug Applications and New Drug Applications, 21 C.F.R. §§ 312 et seq., 314 et seq. (1998).
35journal to publish articles relying on such seemingly limited data, contending that reversing the practice of
male-dominated research will require the cooperation of all entities involved in the ﬁeld of medical research.89
This is just one of many articles that have found an endemic under-representation of women in scientiﬁc
research, as discussed in an earlier section of this paper. How this came about is a product of history, a
misguided yet somewhat admirable attempt to protect women and their potential unborn children, from the
risks of scientiﬁc research. But the unanswered question is why it remains true today, when it is widely
understood that the sex of an individual can play a pivotal role in the body’s response to a drug. In other
words, was it necessary for the other 75.6% of the subjects of the above study to be male? Would the study
results be somehow adversely aﬀected had the percentages of men and women been closer to 50%? Could
drug sponsors use fewer male subjects to accommodate a larger number of female subjects?
No one would suggest the solution to this problem lies in the inclusion of female subjects to the detriment of
male health. But from my research, nobody has examined whether this is really the diﬃcult issue researchers
face. If it were possible to equalize the participation rates by sex without increasing the size of the sample,
many of the cost issues would be eliminated from any discussion on mandating the inclusion of women at a
rate suﬃcient to generate statistically relevant results. One can safely argue that the majority of compounds
consumed everyday has the same eﬀect regardless of whether the consumer is male or female. The crucial
issue becomes ensuring, in the relatively few situations where sex matters, enough women are included in
the sample so that adverse reactions, variations in response, and necessary dosing modiﬁcations are noted
as early in the process as possible.
It is, of course, possible that 75.6% of those subjects had to be male in order for the results to have any
validity for future male patients. If so, it is then necessary to examine the implications of that fact. Whatever
89K. Ramasubbu and D. Litaker, Gender Bias in Clinical Trials: Do Double Standards Still Apply?, Vol. 10, No. 8 J of
Women’s Health & Gender-Based Medicine 757 (October 2001).
36validity is thereby protected by including men at a much higher rate than women necessarily applies, with
any conﬁdence, to men alone. To oﬀer women the same degree of protection would require a signiﬁcant
increase in the size of the sample, which would obviously increase the cost of research and potentially slow
the process. Perhaps this is simply an unavoidable component of drug research. Maybe this is a necessary
requirement so the FDA is able to accomplish its mission of ensuring that only safe and eﬀective prescription
drugs reach the marketplace.
In its report on the higher rate of adverse events among women for certain drugs, the GAO found three
main areas of concern. First, it found a small proportion of women in early clinical studies despite the
acknowledged importance of inclusion at this phase. Second, the FDA and drug sponsors are not taking full
advantage of existing data to determine potential drug reaction diﬀerences between the sexes before the drug
enters the market. Third, the FDA currently employs inadequate management tools to assure compliance
with regulations; as a result, it does not monitor how many women in trials, ensure that reports include the
required tabulations by sex, and train medical oﬃcers adequately to review sex issues in every application.90
It is apparent from this GAO report that institutional changes are also needed within the FDA. Even if women
routinely made up 50% of the samples the problem would persist if it is not adamant about analyzing the
implications of the gathered research. It is distressing to ﬁnd the FDA and sponsors are not taking full
advantage of the research presently collected under the current drug approval process. This is a relatively
simple oversight for the FDA to correct. Likewise, there is no excuse for the failure of monitoring suﬃcient
to secure compliance with its own regulations. The FDA plays an involved role in the drug approval process
90Women Sufficiently Represented in New Drug Testing, but FDA Oversight Needs Improvement, supra note 22,
at 19.
37under the current scheme, so the additional costs, if any, would likely be quite minimal.
Again, while the FDAMA Working Group found that existing procedures were adequate in theory, the
GAO found wide variations in practice. On a positive note, the GAO’s evaluation found that all of samples
included enough women overall to determine statistically the drug’s safety for women. In fact, across all
phases women were 52% of study participants. But there is still not balanced representation across the three
phases of testing. Only 22% of the participants in phase I safety trials, which, as discussed above, are crucial
for calibrating dosage levels, were female.91 In one extreme case, an NDA included no women in the phase
I safety trial.92 In another, a drug was approved for use in men even though the NDA showed that no men
participated in the “pivotal studies.” 93
In addition to questionable inclusion ratios in certain reports submitted to the FDA, the GAO also found
signiﬁcant problems in the enforcement of the 1998 regulation on the tabulation of research results by sex.
The GAO explained:
We found that new drug application summary documents and investigational new drug annual
reports often failed to meet the data presentation requirements of the 1998 regulation. About one-
third of the time new drug application summary documents submitted to FDA by drug sponsors
did not fulﬁll the requirements of the 1998 regulations for the presentation of available safety and
eﬃcacy outcome data by sex. We also found that 39 percent of the investigational new drug annual
reports in our sample did not include the demographic information required by the 1998 regulation.
Although FDA has the authority under its 2000 regulation to suspend proposed research for life-
threatening conditions if men or women are excluded because of their reproductive potential, it has
not yet done so.94




38eﬃcacy data for men and women was omitted in 22% of the applications.95 Both are required under the
terms of the 1998 regulation.
Thirty-six percent of the NDAs reported pharmacokinetic diﬀerences due to weight, whether or not sex
diﬀerences were also noted. Twenty-ﬁve percent reported diﬀerences by sex, but further explained that these
diﬀerences disappeared once weight was held constant. In all cases, weight was the reported cause of any
diﬀerences in response between men and women, so no sex-speciﬁc dosages were recommended. Three NDAs
indicated weight-related dose adjustments based on weight for both male and female patients.96 Yet the GAO
noted that relatively few of the NDAs described studies comparing women on the drug to a placebo group
to determine safety and eﬃcacy speciﬁcally in women. And though all of the sex diﬀerences were declared
clinically insigniﬁcant, some were statistically signiﬁcant.97 (“Clinically signiﬁcant diﬀerences are those that
are judged to be medically relevant, i.e., have a medical eﬀect that should be taken into account, even if they
are not statistically diﬀerent. Conversely, statistically signiﬁcant diﬀerences may not be considered clinically
signiﬁcant.”98) In addition, a signiﬁcant percentage of the NDAs did not report signiﬁcant sex diﬀerences,
and of that group, some failed to include any statistical tests supporting this assertion. As the GAO politely
explains, “Failure to describe a statistical test or report a signiﬁcant diﬀerence does not necessarily mean
that the diﬀerence is not statistically signiﬁcant.”99
The GAO found similar deﬁciencies in the reviewed IND reports. Of the sample reviewed, ﬁfteen percent of
the required annual reports were not submitted; of those submitted, twenty-four percent did not tabulate
the number of males and females in the studies as prescribed by the 1998 regulation. “Only 37 percent of
95Id. at 12.
96Women Sufficiently Represented in New Drug Testing, but FDA Oversight Needs Improvement, supra note 22,
at 17.
97Id. at 13.
98Id. at 10, fn. 16.
99Id. at 15, fn. 24.
39the annual reports tabulated the enrolled study populations by sex, as required by the 1998 regulations; 24
percent of the annual reports stated that there were no ongoing studies.”100 The GAO conducted its review
based on seventy-ﬁve INDs active in November 2000 and required to submit annual report. The remainder
of the INDs, which totaled one hundred in all, consisted of ﬁfteen withdrawn applications, nine for which
annual reports were not required, and one for which the FDA could not ﬁnd the annual report despite records
showing it had been ﬁled with the agency.101
As this discussion shows, the FDA’s oversight of submitted IND reports and NDAs is lacking, as a signiﬁcant
number failed to met the statutory requirements without rebuke from the FDA. To address this in part, the
GAO recommended in its 2001 report a number of management tools including a “demographic worksheet”
and a “standardized template for the medical oﬃcers’ review.”102 This second component was suggested
in response to the documented inattention paid by the reviewers to sex diﬀerences in the approval process.
FDA reviewers, like the drug sponsors in the written reports, did not deem clinically relevant any sex dif-
ference, even those shown statistically signiﬁcant, in any respect (e.g., safety, eﬃcacy, or pharmacokinetics).
Diﬀerences in response appearing between the sexes were attributed to weight, when the distinction was
discussed, not to any cause related speciﬁcally to sex.103
Approximately one third of the reviewed NDAs reported higher concentrations of the drug in the bloodstream
among those who weighed less, a group that typically includes women. Yet the reviewers did not comment
100Id. at 12-13.
101Id. at 13, fn. 21.
102Women Sufficiently Represented in New Drug Testing, but FDA Oversight Needs Improvement, supra note 22,
at 5.
103Id. at 15-6.
40in their summaries about the potential weight diﬀerences that may have existed.104 In fact, FDA’s medical
oﬃcers are not currently required to discuss sex diﬀerences in their reviews.105 The GAO’s report found
that the reviewers “...did not discuss in their written reviews why reported diﬀerences between men and
women in their responses to drugs did not require dose adjustments. In some cases, apparent contradictions
in the NDAs about the role of sex or weight within the text of a drug application were not addressed.”106
Essentially, both the drug sponsors and the FDA routinely ignore the weak rules currently in place regarding
the presentation of data required under the 1998 regulation. Not only do many of the submitted documents
fail to comport with the regulation, but also the FDA fails to suﬃciently question and evaluate the data
that is provided. The GAO’s report concluded:
FDA has not eﬀectively overseen the presentation and analysis of data related to sex diﬀerences in
drug development. There is no management system in place to record and track the inclusion of
women in clinical drug trials or to monitor compliance with relevant regulations, so FDA is unaware
that many new drug application submissions failed to meet standards. The agency also does not
routinely review the required tabulation of demographic data by sex in the annual reports for drugs
in development.107
While the true protection aﬀorded to women under the 1998 regulation is indeed questionable, it is impossible
for it to have even a small degree of eﬀect without stepped up enforcement.
The GAO published a report in January 2003 reviewing the overall operation of the Department of Health
and Human Services, of which the FDA is one component. This January 2003 report repeated the themes




41FDA took full advantage of the data available to learn more about the tested drug’s eﬀects on women and
to explore potential sex diﬀerences in dosing.”108 Furthermore, the GAO emphasized that “[w]hile FDA has
taken some promising initial steps to address these deﬁciencies, it is important that the agency ﬁnalizes the
pilot programs it has under way and give sustained attention to these management issues.”109
Responses to Similar Concerns Relating to Pediatric Patients
The use of prescription drugs in women is not the only area for which the drug approval process and the
FDA have received scrutiny. Many argue that subpopulations are not suﬃciently protected by the existing
framework. As discussed above, once a drug has received market approval from the FDA its use by physicians
is largely unregulated. Doctors have free rein to use the substance in any situation they deem appropriate,
even if the drug sponsor never intended it to be used in such a way. Because of the legality of these oﬀ-label
uses, the drug approval process functions as the only threshold guaranteeing safety.
In recent times, questioning the suitability of the use of approved prescription drugs among pediatric patients
has intensiﬁed, as this is a common oﬀ-label use of prescription drugs.110 Research in pediatric populations
had been almost non-existent due to the obvious ethical concerns. What parent would subject his or her
child to the risks associated in participating in such trials, regardless of the safeguards imposed and the
108Major Management Challenges and Program Risks: Department of Health and Human Services, (GAO-03-101,
January 1, 2003) at 50.
109Id.
110See, e.g., Pediatric Drug Trials: Women and Children Last?, 29 J. of Pediatric Gastroenterology and Nutrition
125, 126 (Aug. 1999) (“The ethical policy of ‘children last,’ at least as far as drug trials are concerned, must be given serious
reconsideration if we are ever to provide the highest quality of care to the children of this country.”).
42potential scientiﬁc beneﬁt? As a result, most prescription drugs were never formally evaluated for use in
children, which also means that the dosing levels were never carefully calibrated in the context of a rigid,
controlled trial. This is not to say that doctors haphazardly prescribe those drugs to their young patients.
Instead of relying upon the results of studies, doctors institute a modiﬁed dosing regime in light of, among
other factors, the drug’s response history in adults and knowledge of the speciﬁc diﬀerences in anatomy,
metabolism, and pharmacokinetics between children and adults.
But this relatively informal (yet often eﬀective) method of determining use and dosages for children has faced
increasing criticism. The FDA stepped in and attempted to expand dramatically the testing of prescription
drugs in children. In 1998 it promulgated “Regulations Requiring Manufacturers to Assess the Safety and
Eﬀectiveness of New Drugs and Biological Products in Pediatric Patients.”111 Manufacturers could obtain
waivers “...if the product does not represent a meaningful therapeutic beneﬁt over existing treatments for
pediatric patients and is not likely to be used in a substantial number of pediatric patients.”112 With respect
to drug products already on the market, the regulation’s impact on manufacturers was somewhat mitigated,
as it placed the burden upon the FDA to show that pediatric studies were necessary.113
The United States District Court for the District of Columbia held, in a 2002 decision, that the regulation
exceeds the FDA’s statutory authority.114 In granting the plaintiﬀ’s motion for summary judgment, the
court found Congress had spoken directly on this issue through the passage of the FDAMA of 1997, thereby
precluding the FDA’s jurisdiction to issue this regulation.115 Finding the statute and the agency’s regulation
11163 Fed. Reg. 66,632 (Dec. 2, 1998).
11263 Fed. Reg. 66,632, 66,634 (Dec. 2, 1998).
11363 Fed. Reg. 66,632, 66,668 (Dec. 2, 1998).
114Ass’n of American Physicians, Inc., et al. v. United States Food and Drug Administration, et al., 226 F. Supp. 2d 204
(D.D.C. 2002).
115Id. at 212.
43“incompatible,” the court held the FDA does not, under current law, possess the power to force manufacturers
to conduct drug trials to determine safe use in children.116 The court’s holding applies to both new drugs
and already-marketed drugs for which the FDA has met the regulatory burden by showing the necessity of
pediatric studies.
As discussed in the court’s opinion, the FDA had proposed the regulation in question at the same time
Congress was debating the FDAMA. Despite the agency’s arguments that Congress’s silence on this speciﬁc
issue signiﬁed approval, the court found it far more signiﬁcant that Congress “...failed to expressly endorse
the Pediatric Rule, even though the FDA requested it do so.”117
Litigation on this regulation continues. The most recent published action, as of the writing of this paper,
was a denial of a motion for expedited consideration of appeal, which was issued on February 5, 2003.118
Without this regulation, there still remains intact Congress’s attempt to remedy the lack of pediatric studies
demonstrating safety and eﬀectiveness through part of the 1997 FDA Modernization Act. To overcome the
deﬁciency, the Act creates incentives for manufacturers to conduct pediatric safety trials, with the choice to
do so remaining with the drug’s sponsors. In exchange for documented safety for use in pediatric patients,
drug manufacturers are granted an additional six months of market exclusivity following the expiration
of a patent or market exclusivity, whichever is longer.119 This section of the 1997 Act included a sunset
provision, eﬀect January 1, 2002, and required the Commissioner to report to Congress by January 1, 2001 on
the experience and eﬀectiveness of the incentive.120 The “Best Pharmaceuticals for Children Act” (“BPCA”)
was enacted on January 4, 2002, three days after the sunset provision took eﬀect.121 This new legislation is
116Id. at 220.
117Id. at 219-20.
1182003 U.S. App. LEXIS 2079 (Feb. 5, 2003).
11921 U.S.C. § 355(a)
120Pub. L. No. 105-115 § 111 (j) & (k), 111 Stat. 296 (1997)
121Pub. L. No. 107-109, 115 Stat. 1408 (2002)
44scheduled to expire on October 1, 2007.122
The new legislation does more than continue the practice of granting an additional six months of market
exclusivity when the desired research results are shared with the FDA. Now, the FDA has the authority
to request pediatric studies of drugs already on the market if it can show potential health beneﬁts. The
FDA is now instructed to weigh the importance of adequate representation of ethnic and racial minorities
among the pediatric participants when considering protocols.123 (This may prove meaningless, however,
if such subpopulations are not suﬃciently represented to generate reliable statistical results). The BPCA
also created the “Oﬃce of Pediatric Therapeutics” to coordinate all activities within the agency that may
involve children’s issues.124 This oﬃce is also to receive, for a year following the grant of the six-month’s of
additional market exclusivity, any adverse event of which the FDA becomes aware.125
The BPCA provides a contrast to the approach taken to address sex diﬀerences in prescription drug responses.
While the BPCA does not mandate pediatric testing, it does recognize and address a potentially serious loop-
hole existing in the drug approval process and the unregulated use by doctors of prescription drugs. Congress
recognized that socially desirable pediatric studies were not being conducted, perhaps because drug sponsors
lacked suﬃcient market incentives. Unlike as with the well-documented under-representation of women in
drug trials, the government did more than encourage the inclusion of children in samples and require the
tabulation of pediatric data within the NDA. It went a signiﬁcant step further by creating a speciﬁc incen-
tive to encourage the desired research, and the BPCA provides the FDA with a mechanism to request the
information when it determines necessary.
122Pub. L. No. 107-109, 115 Stat. 1408 (2002) at § 8.
123Pub. L. No. 107-109, 115 Stat. 1408 (2002) at § 18(a).
124Pub. L. No. 107-109, 115 Stat. 1408 (2002) at § 6.
125Pub. L. No. 107-109, 115 Stat. 1408 (2002) at § 17(b).
45Congress’s actions do not, however, amount to complete solution. Under current statutory and case law, the
FDA still does not possess the authority to mandate pediatric trials. Out of practical necessity, prescrip-
tion drugs remain available for use in children without corresponding studies to guide their use. But it is
interesting to note that both Congress and the FDA acted to address the dearth of information about the
relationship between children and the prescription drugs prescribed to them.
This discussion of the BPCA is not presented as a model of desirable congressional action to correct for
insuﬃcient consideration of sex diﬀerences. Instead, it demonstrates that the political capital exists, in
Congress and in the FDA, to make changes to expand the protective scope of the drug approval process.
Concluding Thoughts and Unanswered Questions
The fundamental problem with the current drug approval process, involving both the FDA and drug spon-
sors, is that the male sex is still treated as the baseline, as the norm. This view is still evident in current
medical literature.126 Women are often treated as a special category, usually referred to in the same breath
as minorities. In the end, this is no better than the approach of the seventies that associated pregnant
women with truly vulnerable groups like the mentally handicapped or incarcerated individuals. Despite the
fact women make up over half of the population, and medical literature is replete with fundamental biological
diﬀerences between the sexes that extend far beyond the reproductive systems, the current drug approval
process does not protect women. And while research has continued to emphasis the often-startling diﬀerences
between men and women, women are still not adequately represented in medical research. This practice may
126Committee on Understanding the Biology of Sex and Gender Differences, Institute of Medicine, supra note 1,
at 24.
46be much less intentional and overt than it was when the drug approval was ﬁrst institutionalized, but the
subtle and insidious lack of attention paid to women patients by researchers and the FDA continues.127
It would be inappropriate to extend this position into an argument for the passage of the “Best Pharmaceuti-
cals for Women” Act or the equivalent. Instead, the FDA needs to expand it perception of the drug approval
process so that sex diﬀerences are properly respected within the existing framework.128 The true problem
is that the current approval process pretends to address the needs of all, especially all adults, when this is
generally not the case. While it may be true that, when reviewed in the abstract, the drug approval process
itself is not sexist, the results of the system are, at best, questionable. When signiﬁcant diﬀerences between
the sexes are routinely ignored in clinical trials, and recently pulled prescription drugs disproportionately
aﬀected women and not men, it is time to question the process.
On average, women live longer, visit doctors more often, undergo complex procedures more frequently, have
more lab tests, take more medication, and spend more time in hospitals than men.129 Despite being more
frequent customers, the medical establishment exhibits a subtle yet wide-ranging bias against women. For
example, some recent studies have shown that Medicare provides better coverage for those conditions more
frequently seen in men as compared to those conditions more prevalent in women. There is also a pervasive
lack of medical research about women and conditions in women. For some, this can have immediate and
dramatic eﬀects. For example, many insurance policies exclude coverage for procedures deemed experimental
or investigational, so women are disproportionately aﬀected by this seemingly sex-neutral policy.130
127See, e.g., K. Ramasubbu and D. Litaker, Gender Bias in Clinical Trials: Do Double Standards Still Apply?, Vol. 10, No.
8 J. of Women’s Health & Gender-Based Medicine 757, 760 (October 2001) (Five trials published in the New England
Journal of Medicine during a ﬁve year period expressly excluded women of child-bearing potential without detailing speciﬁc
rational. Why did the researchers do this? Why did the editors of the Journal not question this?).
128See also Marianne N. Prout & Susan S. Fish, Participation of Women in Clinical Trials of Drug Therapies: A Context for
the Controversies, 6 Medscape Women’s Health E-Journal (Oct. 2001) (After reviewing history of women’s participation
in drug trials suggests enforcement of existing regulations and procedures to eﬀectuate necessary changes).
129Women’s Health Law Symposium, Rutgers School of Law-Newark, supra note 12, at 18.
130Id. at 22.
47Some commentators have called for the mandatory inclusion of women in studies, such as the clinical drug
trials that determine the outcome of the drug approval process, concluding this is only reliable way to ensure
that women are suﬃciently represented.131 They acknowledge that such a move would inevitably result in
higher research costs, but question the validity of using cost concerns as an argument against the proposal.
The underlying assumption of a statement like that is that costs incurred as a result of male-dominated
research are appropriate, but the additional expense associated with protecting women would somehow be
excessive.132 It is interesting to note, however, there is some evidence the FDA believes actions to equalize
the rate of participation between the men and women will not be prohibitively expensive.133
The prescription drug approval process can never be perfect. Even in the best-case scenario, the FDA, as a
matter of necessity, makes approval decisions based on the results of studies conducted on random samples.
There is no way to ensure that rare adverse reactions will appear in the collected data, and certain eﬀects
will inevitably become visible only after signiﬁcant time has passed. Against this risk the FDA must weigh
the risks to the population known to need access to treatment for a given condition.134 “Once a drug is
approved for marketing and used by potentially hundreds of thousands of patients, however, the type, rate,
and severity of adverse events caused by the drug can be much diﬀerent than those detected during the
drug’s development.”135
The FDA cannot guarantee safety or eﬀectiveness, but it can ensure that the drug approval processes
functions so as many people are protected as is feasible. A signiﬁcant, yet relatively easy, step would be
131Id. at 30. Cf. Curtis L. Meinert, The Inclusion of Women in Clinical Trials, 269 Science 795 (Aug. 11, 1995) (Argues
against imposition of quotas or the equivalent to ensure adequate representation of sub-populations).
132Id. at 29.
133Linda Ann Sherman, Robert Temple, & Ruth B. Merkatz, Women in Clinical Trials: An FDA Perspective, 269 Science
793, 795 (Aug. 11, 1995) (...”FDA expects sponsors to study the full range of patients likely to receive a drug, including both
genders, and to analyze the data to determine whether responses in various groups are diﬀerent. This expectation is not new
and implementing it is not likely to add signiﬁcantly to drug development costs.”)
134Higgs, supra note 30 at 21.
135Drug Safety: Most Drugs Withdrawn in Recent Years Had Greater Health Risks for Women, supra note 78.
48for the agency to increase enforcement of the regulations already in place about the presentation of data in
the reports submitted to the FDA. It would also not require much of the FDA’s resources to educate its
evaluators about the importance of sex in drug responses so that it becomes a more signiﬁcant feature of
the drug’s overall evaluation.
Beyond these relatively easy changes in practice the FDA should adopt lies the far more diﬃcult and
contentious issue about proposals to mandate the inclusion in women subjects in numbers suﬃcient to
generate statistically signiﬁcant results. The immediate response to such an idea is that it would prohibitively
expensive due to the increase in the overall sample size it would entail. But is this true? Are men currently
over-represented so that a possible solution would be to replace some male subjects with females? Are women
equally willing to participate in clinical drug trials?136
For women to enjoy the same level of protection, they must participate in equal numbers in the drug approval
process. “Being a research subject does involve risks, but the risks created by our current lack of knowledge
about women’s health are far more signiﬁcant.”137
To address the answer posed in the title of the paper, it is highly unlikely that the FDA is truly sexist in its
administration of the drug approval process. It is equally true, however, that the current system continues
to rely more on male subjects and to result in more problems for female patients as compared to males.
What is needed is a careful, unbiased examination of why researchers continue to rely primarily on male
study subjects. Additional research is needed to determine whether incorporating more women in the drug
trials, either by supplanting males or in addition to the current number of male subjects, would actually
136Dr. Vivian Pinn, director of the Oﬃce of Research on Women’s Health at the National Institutes of Health, says that
is not diﬃcult to get women involved in studies. In fact, women want to know of the existence of the studies and want to
participate. Popular misconceptions about women’s health and emerging trends in medical research transcript, Talk of the
Nation, National Public Radio, Host: Neal Conan (July 30, 2002).
137Women’s Health Law Symposium, Rutgers School of Law-Newark, supra note 12, at 23.
49increase research costs in a dramatic fashion. Once this information is gathered, important policy questions
will have to be answered within the agency and by Congress.
If there is no other way to ensure women are represented in the drug approval process but to signiﬁcant
increase the sample size, thereby increasing the costs of drug research, Congress, the FDA, and the medical
research community must evaluate the implications of such a ﬁnding. Perhaps the additional expense is
simply unavoidable to eﬀectuate the FDA’s mission of ensuring only safe and eﬀective drugs reach the
market.
Despite its limitations, the drug approval process has proven to be a reliable method for ensuring the safety
of drugs, at least for men. The process must be further evaluated so that the same can be said conﬁdently
for women.
50